Tau PET/CT in Various Tau-Related Disease Patients

Launched by TIANJIN MEDICAL UNIVERSITY · Nov 14, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a special imaging test called 18F-S16/T807 PET/CT, which helps doctors see certain changes in the brain related to conditions known as tauopathies. These are diseases that involve the buildup of a protein called tau, which is linked to neurodegenerative diseases, such as Alzheimer's. The goal of the study is to find out how useful this imaging test is for diagnosing both primary tumors and those that have spread to the brain in patients with these tau-related diseases.

To participate in this trial, you need to be an adult aged 18 or older who has either newly diagnosed or previously treated malignant tumors and is scheduled for a Tau PET/CT scan. It's important that you can give your consent to join the study. However, people with non-cancerous lesions, those who are pregnant, or those unable to provide consent cannot participate. If you join, you can expect to undergo this advanced imaging procedure, which may help researchers understand more about tau-related diseases and improve future diagnosis and treatment options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Tau PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
• Exclusion Criteria:
• • - (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.